Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Preparación duradera de inyectable de melatonina con estabilidad a largo plazo

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20160617002
Publicado:
30/06/2016
Caducidad:
30/06/2017
Resumen:
Un grupo de investigación del Sistema Sanitario Público de Andalucía (SSPA) ha desarrollado una nueva composición inyectable de melatonina con estabilidad a largo plazo. Esta composición es útil como medicamento en varias enfermedades: enfermedades cardíacas e inflamatorias y septicemia en recién nacidos y adultos. La tecnología está protegida por una patente. El grupo de investigación busca socios con el fin de establecer acuerdos de licencia y centros de I+D, centros tecnológicos o empresas especializadas para colaborar en el desarrollo de la tecnología mediante acuerdos de cooperación técnica.



Details

Tittle:
Durable preparation of an injectable melatonin with long-term stability, developed by a Spanish research group.
Summary:
A research group of the Andalusian Public Health System (SSPA) has developed a new injectable composition of melatonin which has a long-term stability. Therefore, it is ideal for being used as a medicine in several health conditions.

This research group is seeking to establish a licensing agreement or an agreement of public-private partnership in order to develop such technology (technical cooperation agreement).
Description:
This research group of the Andalusian Public Health System (SSPA) is supported by an Andalusian University, has expertise in biomedical research and this invention consist mainly of an enhanced melatonin solution.

Nowadays, the melatonin is used to treat different diseases like epilepsy, sleep disorder, some cases of sepsis, and cardio protective treatment after acute myocardial infarction, some inflammation cases, and oxidative stress after surgery, among others. It generally shows low toxicity, safety, efficacy and absence of side effects, when administrated in different doses via intravenous. The current aqueous compositions remain stable for a period of approximately three months. It is necessary to increase its durability, thus, this research group have focused on offering a solution to this issue.

This research group has developed an aqueous composition of melatonin that has shown remarkable long-term stability. Therefore, it allows the presence of concentrations of such water-insoluble active ingredient. Thanks to the properties of such composition, it is useful as injection, i.e. for the intravenous medicine administration. In this sense, its application as a drug can treat cardiac and inflammatory conditions as well as sepsis in neonates and adults.

The research group aims to formalize a technology transfer process with entities interested in the implementation of the solution, through license agreement. If there are some entities, such as R-Y-D centers, technology centers or specialized companies, interested in collaborate and develop further aspects of the solution, a technical cooperation agreement could be envisaged.

This technology is protected by patent.
Advantages and Innovations:
This new composition is made of a physiologically tolerable material, whose administration has a low risk of allergies, side effects, adverse events or other similar reactions, i.e. gastric upset, dizziness. In fact, it is free of pyrogens.

Besides, its use is quite wide. This composition of melatonin has an increased long-term stability; it can be used as a medicine and for the treatment of various health conditions.
This invention has a competitive advantage, in addition to the above-mentioned features: it can be used during the production of medicine and it was approved by the Spanish Medicines Agency for the clinical trial.
Stage of Development:
Field tested/evaluated
IPs:
Patents granted
CommeR Statunts Regarding IPR Status:
International patent PCT

Partner sought

Type and Role of Partner Sought:
Type of partner sought:
SMEs, companies, hospitals and R-Y-D Institution


Field of activity:
Pharmacology, medicine

Task to be performed by the partner:
-Arrangement of the condition of the license agreement and co-working for the implementation of the solution

-Co-development of further aspects of the solution and its improvement

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001002 Investigaciones clínicas, ensayos
06001012 Investigaciones médicas